<DOC>
	<DOCNO>NCT01702038</DOCNO>
	<brief_summary>The purpose study determine B cell subset autoantibodies related disease remission rituximab treatment subject Systemic Lupus Erythematosus ( SLE ) .</brief_summary>
	<brief_title>Determining Responses Impact Rituximab-instigated Cell Depletion T Cells People With SLE</brief_title>
	<detailed_description>Immune cell important part abnormal autoimmune response SLE . The B cell significant part autimmune response produce antibody react normal tissue body . B cell ability accumulate promote development SLE . The purpose study determine B cell subset autoantibodies related disease remission rituximab treatment subject SLE . This study last approximately two year consist 15 study visit . These visit occur screen , baseline , Days 0 14 , Months 1 , 2 , 3 , 4 , 6 , 9 , 12 , 15 , 18 , 21 , 24 . Participants receive single rituximab injection Days 0 14 . Medication history blood test occur every study visit . A physical exam , medical history , urine test occur visit . For female , pregnancy test occur select visit .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Diagnosis SLE Positive ANA titer least 1:160 Active disease ( one modify BILAG A B ) inability lower steroid leass 20 mg/day . More information criterion find protocol . For female , must agree use effective birth control method duration study Severe thrombocytopenia Active , moderate , severe proliferative glomerulonephritis Active CNS manifestation due lupus migraine , mild cognitive dysfunction , mood disorder . More information criterion find protocol . Poorly control antiphospholipid syndrom Significant organ dysfunction Conditions , SLE , likely require prolonged systemic steroid Chronic infection . More information criterion find protocol . Hepatitis B infection Hepatitis C infection Deep space infection within two year study entry Severe bacterial infection within three month study entry More one severe bacterial infection within two year study entry Positive purify protein derivative tuberculin skin test History cancer , include basal cell carcinoma carcinoma situ cervix documentation successful treatment Alcohol drug abuse Surgery within three month study entry Immunization live vaccine within two month study entry Any immunization within one month study entry Received cyclophosphamide calcineurin inhibitor within six month study entry Received antiTNF alpha antibody within 3 month study entry Received etanercept within one month study entry Received antiCD20 antibody lymphocyte deplete antibody Received Immunoglobin G infusion protein monoclonal antibody Treatment FDA nonapproved agent within six month study entry Transaminases great two time upper limit normal Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>